Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Los artículos de esta sección se muestran en inglés.
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Trade News, 2026-10-02 resume el mercado: Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes. Fuente primaria: original en CNBC Top News (cnbc.com).